Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
A Vertex partner — and potential rival — secures $100M to …
Dec 18, 2024 · SiteOne has a complicated relationship with Vertex. Its lead program also regulates NaV1.8, meaning the companies may one day be competitors. Yet they are also working together on a different non-opioid pain drug that targets the “NaV1.7” sodium channel.
With new data, Lilly sets pace for next wave of breast cancer drugs
Dec 11, 2024 · An experimental breast cancer drug developed by Eli Lilly met its main goal in a Phase 3 study, helping people with a form of HER2-negative, ER-positive disease stay alive and progression free for longer than standard hormone-suppressing therapies, according to data disclosed Wednesday.. When combined with Lilly’s approved medicine Verezenio, the experimental drug, called imlunestrant, also ...
Sanofi, Teva say study results show gut disease drug could be …
Dec 17, 2024 · Dive Brief: An experimental drug co-developed by Teva and Sanofi met its main objectives in a mid-stage clinical trial in inflammatory bowel disease, showing what the partners claimed to be “best-in-class potential.”; Around half of people with ulcerative colitis who received a high dose of the drug, duvakitug, in a Phase 2 trial had their symptoms resolve after 14 weeks, versus just over ...
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson
Jan 16, 2025 · Novartis’ dealmaking plans. Novartis spent billions of dollars snapping up companies in 2023 and 2024, from radiopharmaceutical developer Mariana Oncology to Kate Therapeutics and its experimental gene therapies.The company will remain an active dealmaker in 2025, according to Fiona Marshall, Novartis’ president of biomedical research.
Merck calls quits on two immunotherapies for cancer
Merck & Co. on Dec. 16, 2024, cancelled work on combination therapies with its cancer drug Keytruda. Sundry Photography via Getty Images
GSK taps a startup for shot at Alzheimer’s drug | BioPharma Dive
Dec 5, 2024 · Inside every human cell are thousands of snippets of genetic code that serve as the directions for creating proteins. And over the past four years, a small biotechnology company has been trying to prove that, by looking closely enough at this assembly of instructions, it can find new ways to treat diseases like Alzheimer’s, Parkinson’s and multiple sclerosis.
Kailera Therapeutics emerges from stealth with $400M for obesity …
Oct 1, 2024 · Kailera’s early investors include Atlas Venture, Bain Capital, RTW Investments and Lyra Capital. In May, the venture firms incorporated the company and licensed the drug candidates from Hengrui for $110 million in upfront and near-term payments as well as a roughly 20% equity stake, according to a filing. Bain Capital, where Renaud is a partner, held the largest stake in Kailera as of May at ...
Roche’s TIGIT-targeting drug for cancer fails its biggest test
Nov 26, 2024 · Tiragolumab is aimed at an immune cell protein called TIGIT, a drug target that was uncovered by scientists at Roche’s Genentech subsidiary. Researchers there have been studying TIGIT’s role in suppressing the immune system’s response to cancer for more than a decade.Tiragolumab, which binds to TIGIT to block those signals, was the result of their efforts and, after promising mid-stage ...
Pfizer drug for hemophilia approved by FDA | BioPharma Dive
Oct 14, 2024 · Dive Brief: The Food and Drug Administration on Friday approved a new kind of medicine for hemophilia, clearing Pfizer’s Hympavzi for people with either the “A” or “B” forms of the inherited bleeding condition.; Adults and children 12 years of age or older who haven’t developed proteins, or “inhibitors,” that prevent clotting drugs from working well are eligible to …